What Happened

Between August and October 2016, Victor Van Cleave, a pharmacy technician at Iowa Methodist Medical Center in Des Moines, diverted approximately 252 vials of fentanyl and 18 vials of hydromorphone intended for patient care.

Van Cleave used a syringe to withdraw fentanyl and hydromorphone from vials, replaced the drugs with sterile water, and returned the tampered vials to pharmacy stock — where they could be dispensed to patients as though unaltered. The scheme relied on the fact that the vials stayed in inventory, so counting them revealed nothing.

Federal prosecutors charged Van Cleave with illegally tampering with fentanyl. He was sentenced on July 10, 2018, to 30 months in federal prison. The hospital subsequently notified more than 180 patients who may have received tampered product, underscoring how substitution-based diversion converts drug theft into a direct patient safety event.

What Went Wrong

This case illustrates how substitution-based diversion defeats inventory counting and requires physical-product controls rather than quantity controls alone. Several control failures converged:

  • A pharmacy technician with stocking and returns duties had unsupervised access to controlled substance vials — access that could be exploited without any second-person verification.
  • Returned vials were not visually or physically inspected for seal integrity or content changes, so a sterile-water substitution was indistinguishable from legitimate product.
  • Inventory reconciliation could not detect the theft because the tampered vials remained present and countable; the drug was gone but the vial was not.
  • Surveillance focused on dispensing records rather than on the integrity of product in pharmacy storage, leaving the tampering window invisible.

How It Could Have Been Prevented

  • Require two-person verification for any controlled substance vial removed from and returned to pharmacy stock, with both parties signing the transaction.
  • Inspect returned vials for seal and label integrity, and quarantine any vial with signs of tampering pending investigation.
  • Apply physical or analytical integrity checks — such as weight verification or tamper-evident packaging — to high-risk injectable opioids in pharmacy storage.
  • Limit pharmacy technician access to controlled substance storage to defined restocking windows, with access-log review for out-of-pattern activity.
  • Extend diversion surveillance to pharmacy staff, benchmarking access and handling patterns against peers rather than clinical staff alone.
  • Conduct periodic unannounced physical counts that compare vial weight or content against expected values, not just vial presence.

Related Guidance

Sources